PCV51 Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Adult Patients With Non-Valvular Atrial Fibrillation with One or More Risk Factors – A UK Perspective
Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.994
https://www.valueinhealthjournal.com/article/S1098-3015(12)02707-6/fulltext
Title :
PCV51 Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Adult Patients With Non-Valvular Atrial Fibrillation with One or More Risk Factors – A UK Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02707-6&doi=10.1016/j.jval.2012.08.994
First page :
A371
Section Title :
Cardiovascular Disorders
Open access? :
No
Section Order :
499